SCHEMBL6785174

SCHEMBL6785174

COc1cc(OC)c(/C=C/C=C/C(=O)O)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ABCG2 Q9UNQ0 4/20 0.58
PTGS2 P35354 2/20 0.55
MAOA P21397 2/20 0.51
CYP1A1 P04798 2/20 0.50
CYP1B1 Q16678 2/20 0.50
CYP1A2 P05177 1/20 0.50
AURKA O14965 1/20 0.49
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
ERN1 O75460 1/20 0.47
HSD17B10 Q99714 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
HTR1A P08908 1/20 0.46
HTR2C P28335 1/20 0.46
PKM P14618 1/20 0.46
PTGS1 P23219 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715946 0.88 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2ABCG2PTGS2MAOA
SCHEMBL290189 0.88 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2ABCG2PTGS2MAOA
SCHEMBL6792466 0.81 ABCG2 (0.58) ALDH1A1SMN1; SMN2ABCG2CYP1A1CYP1B1
SCHEMBL10661702 0.81 MAPT (0.69) ALDH1A1SMN1; SMN2CYP1A1CYP1B1CYP1A2
SCHEMBL6782178 0.81 MAPT (0.69) ALDH1A1SMN1; SMN2CYP1A1CYP1B1CYP1A2
SCHEMBL6787725 0.79 CYP1A1 (0.55) ALDH1A1SMN1; SMN2ABCG2PTGS2MAOA
SCHEMBL30185807 0.79 CYP1A1 (0.55) ALDH1A1SMN1; SMN2ABCG2PTGS2MAOA
SCHEMBL26445244 0.78 ABCG2 (0.64) ALDH1A1SMN1; SMN2ABCG2PTGS2MAOA
SCHEMBL1877387 0.77 ABCG2 (0.68) ALDH1A1SMN1; SMN2ABCG2PTGS2MAOA
SCHEMBL1877390 0.77 ABCG2 (0.68) ALDH1A1SMN1; SMN2ABCG2PTGS2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828316-B2 Antiallergens KOWA CO., LTD. (JP) 2004-12-07 US disclosed
US-20020042414-A1 Diamide compound and medicine containing the same KOWA CO., LTD. (JP) 2002-04-11 US disclosed
US-6340682-B1 FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS KOWA CO., LTD. (JP) 2002-01-22 US disclosed
EP-0926138-A1 DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO. LTD. (JP) 1999-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042414-A1 Diamide compound and medicine containing the same HRH4, HRH2, HRH1 ALDH1A1 836/4885SMN1; SMN2 4780/4885ABCG2 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.